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Abstract
Background:  Gene expression profiling has recently shown that the mRNA for CD24 is
overexpressed in prostate carcinomas (Pca) compared to benign or normal prostate epithelial
tissues. Immunohistochemical studies have reported the usefulness of anti-CD24 for detecting
prostate cancer over the full range of prostate specimens encountered in surgical pathology, e.g.
needle biopsies, transurethral resection of prostate chips, or prostatectomies. It is a small mucin-
like cell surface protein and thus promises to become at least a standard adjunctive stain for atypical
prostate biopsies. We tested the usefulness of real-time RT-PCR for specific and sensitive
detection of CD24 transcripts as a supplementary measure for discriminating between malignant
and benign lesions in prostatic tissues.
Methods:  Total RNA was isolated from snap-frozen chips in 55 cases of benign prostatic
hyperplasia (BPH) and from frozen sections in 59 prostatectomy cases. The latter contain at least
50% malignant epithelia. Relative quantification of CD24 transcripts was performed on the
LightCycler instrument using hybridization probes for detection and porphobilinogen deaminase
transcripts (PBGD) for normalization.
Results: Normalized CD24 transcript levels showed an average 2.69-fold increase in 59 Pca-cases
(mean 0.21) when compared to 55 cases of BPH (mean 0.08). This difference was highly significant
(p < 0.0001). The method has a moderate specificity (47.3%) but a high sensitivity (86.4%) if the
cutoff is set at 0.0498. CD24 expression levels among Pca cases were not statistically associated
with the tumor and lymph-node stage, the grading (WHO), the surgical margins, or the Gleason
score.
Conclusion: The present study demonstrates the feasibility of quantitative CD24 RNA transcript
detection in prostatic tissues even without previous laser microdissection.
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Background
Since 2003, prostate cancer has been the tumor with the
highest incidence among men in the Federal Republic of
Germany. Approximately 40,600 new cases and 11,100
deaths from this disease were reported for this year in Ger-
many [1]. A precise pathological classification is of essen-
tial importance for treating both localized and advanced
tumors. Established conventional prognostic markers are
prostate-specific antigen (PSA) [2], the tumor stage and
grade [3], the patient's age [4], and the presence of resid-
ual tumor(s) [5].
PSA shows high sensitivity but very low specificity as a
serum marker for prostate cancer. This leads to an enor-
mous increase of basically superfluous prostate biopsies
and resultant high costs [2].
Although most of the initially diagnosed tumors are
organ-confined (pT2 stage), they are still highly variable
in their clinical outcome. This points to the shortcomings/
limits of the classical prognostic markers and underscores
the need for improved markers.
A comparison of benign, organ-confined, and highly
advanced tumors using gene expression profiling tech-
niques has recently disclosed several new molecular mark-
ers with prognostic value for prostate cancer [6-8]. A
similar approach was used to unmask CD24 as a signifi-
cant predictor of PSA relapse and poor prognosis in low-
grade prostate cancer [9]. CD 24 is a small, heavily glyco-
sylated, mucin-like cell surface protein [10]. It is expressed
in granulocytes and various developing cells, including
pre-B cells, keratinocytes, and renal tubular epithelium,
but also in a large variety of malignancies [11-20]. CD24
is a ligand of P-selectin and could thus promote the dis-
semination of CD24-positive tumor cells [21].
We evaluated the expression of CD24 by quantitative flu-
orescence-based real-time RT-PCR (LightCycler) as an
alternative to the predominant immunohistolological
staining procedures (CD24-specific monoclonal antibod-
ies).
Our aim was to determine whether QRT-PCR-based detec-
tion of CD24 will yield data with sensitivity and specifi-
city comparable to those in existing reports based entirely
on immunohistochemical staining. In this case, quantita-
tive CD24 mRNA evaluation could supplement the
pathologist's subjective analysis in doubtful cases.
The study thus examined 55 probes obtained in cases of
benign prostatic hyperplasia (BPH) and 59 from patients
with prostatic adenocarcinoma (Pca).
Methods
Patients and tissues
Probe retrieval was done in agreement with the Helsinki
Declaration. Institutional review board approval was
obtained for this study. All patients signed a consent form
approved by the Committee on Human Rights in
Research at our institution.
The study examined tissues obtained by transurethral
resection (TUR-P) in 55 patients with benign prostatic
hyperplasia (BPH) and 59 with prostatic adenocarcinoma
(Pca) as well as specimens from radical prostatectomies in
51 cases, and tissue chips from 8 palliative TUR-Ps.
Table 1: Pathological Classification (59 Prostate carcinoma cases).
Grading (WHO) Gleason-Score
G1 3 5.1% Median 6
G2 31 52.5% Mean 6
G3 25 42.4% Range 3 – 9
Total 59 100% N 59
Local staging Lymph Nodes
localized 25 42.4% Negative 42 71.2%
local advanced 26 44.1% Positive 14 23.7%
unknown 8 13.5% Unknown 3 5.1
Total 59 100% Total 59 100%
Margins Distant Metastasis
Negative 34 57.6 No distant metastasis 57 96.6%
Positive 11 18.7 Distant metastasis 2 3.4
Unknown 14 23.7
Total 59 100% Total 59 100%BMC Urology 2006, 6:7 http://www.biomedcentral.com/1471-2490/6/7
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In all cases, tissues were removed and immediately snap
frozen in liquid nitrogen and stored at -80°C until further
processing. Ten 30 µm frozen sections were prepared from
each tissue sample with the aid of a Cryostat 2800 (Leica
Instruments GmbH, Nussloch, Deutschland) and stained
with hematoxylin-eosin.
These sections were stored for later RNA extraction. An
additional 10 µm section was used to analyze tumor com-
ponents
Samples from cancer patients were microscopically exam-
ined by an uropathologist (J.K.).
The examined blocks were divided into two groups based
on the percentage of malignant cells they contained:
1: 0 – 50 % malignant cells
2: more than 50% malignant cells
Only specimens with a carcinoma component of at least
50% were selected for further mRNA analysis.
Follow-up
At the time of sample processing, information on the cur-
rent PSA and any clinical progression was obtained by tel-
ephone. Here a PSA of over 0.02 ng/ml was assessed as
progression in the 51 radical prostatectomy cases, whereas
progression had to be clinical, e.g. new metastases, to be
evaluated as such in the 8 palliative TUR-P cases.
RNA extraction and reverse transcriptase-polymerase 
chain reaction (RT-PCR)
RNA was prepared from tissue samples using EZ1 BioRo-
bot™ (QIAGEN, Hilden, Germany) according to the man-
ufacturer's instructions. The RNA concentration and
quality (28S/18S) were determined after capillary electro-
phoresis using RNA Nano LabChip® technology using an
AGILENT Bioanalyzer 2100 instrument (Agilent GmbH,
Waldbronn, Germany).
Quantitative RT-PCR
Real-time one-step RT-PCR for detecting CD24 mRNA
was performed using a LightCycler thermal cycler system
according to the manufacturer's instructions (Roche Diag-
nostics GmbH, Mannheim, Germany).
Amplification primers for CD24 were 5'-TGAAGAACAT-
GTGAGAGGTTTGAC -3' (sense) and 5'-GAAAACT-
GAATCTCCATTCCACAA -3' (antisense). A hybridization
probe-type protocol (GGATGTTGCCTCTCCTTCATCTTG-
TACATG-FL, FL probe; 5'-AACTCCAGC-AGATTTAATATT-
GGCATTCATCA-PH-3', LC Red640-probe) was used to
detect the 208 bp product.
For one-step RT-PCR, 250 ng of RNA were first reverse-
transcribed into cDNA for 10 min at 55° and later ampli-
fied for 45 cycles (1 sec @ 95°C, 15 sec @ 58, 20 sec @
72°C)
The housekeeping gene was amplified using the porpho-
bilinogen deaminase (PBGD) housekeeping gene kit
(Roche Diagnostics GmbH, Mannheim, Germany). To
amplify the target gene CD24, the LightCycler RNA ampli-
fication kit was used in combination with CD24-specific
primers (Roche Diagnostics GmbH, Mannheim, Ger-
many).
Evaluation
LightCycler software version 3.3 (Roche Diagnostics) was
used to analyze PCR kinetics and calculate quantitative
data. A standard curve generated in a separate run was
loaded into runs of patient samples (without standard
curves). Each run included one sample of known concen-
tration and in the range covered by the standard curve,
thus allowing estimation of exact copy numbers by the
second derivative maximum method.
For each sample, copy numbers of CD24 mRNA were
divided by those of PBGD mRNA to normalize for CD24
mRNA expression and thus avoid sample-to-sample dif-
ferences in RNA quantity.
CD24 expression in prostate carcinoma (Pca) cases vs.  benign prostatic hyperplasia (BPH) cases Figure 1
CD24 expression in prostate carcinoma (Pca) cases vs. 
benign prostatic hyperplasia (BPH) cases. (n = 114; 55 BPH + 
59 Pca) Median, Quartiles (25%, 75%), Outliers (5%, 95%), 
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Statistical analysis
Data were recorded and statistically analyzed using Micro-
soft® Excel XP® and SPSS for Windows® in Version 13.0.1.
Normal distribution was checked. Statistical differences
were detected by Student's t test. Results with a two-sided
p value of ≤ 0.05 were assessed as significant. A Wilcoxon
test was carried out in cases where a normal distribution
was not found. The values are plotted on a ROC curve to
analyze the extent to which the relative CD24-mRNA
expression can differentiate cancer from benign findings.
An area under the curve is calculated (from 0.0 to 1.0),
and a coordinate table is used to select a favorable inter-
section point of sensitivity (ordinate) and specificity
(abscissa). This is the cutoff.
Results
This study included 120 prostatic tissues, of which 114
met our RNA quality standards with regard to the presence
of 28S/18S RNA (BPH = 55 of 59; Pca 59 of 61). The
median PSA was 2.8 ng/ml in the BPH patients and 9.76
ng/ml in the Pca patients. Table 1 shows the pathological
parameters of the Pca patients.
Graphs depict relative CD24 expression results in Figures
1 and 2.
The mean relative CD24 expression value was 0.21 (range
0.013–1.02; median 0.14) in the Pca group and 0.08
(range 0.01–0.29; median 0.06) in the BPH group. This
Pca patient population had a 2.69 times higher mean
CD24 expression for Pca than for BPH. This difference was
highly significant (p < 0.0001). Analysis of the CD24-
ROC curve (Figure 3) shows a moderate specificity
(47.3%) but high sensitivity (86.4%) if the cutoff is set at
0.0498. The Area under the curve was 0.754. The positive
predictive value was 64.9% (50/77 patients), whereas the
Detailed CD24-mRNA-expression in each case (n = 114; 55 benign prostatic hyperplasia (BPH) + 59 prostate carcinoma (Pca) Figure 2
Detailed CD24-mRNA-expression in each case (n = 114; 55 benign prostatic hyperplasia (BPH) + 59 prostate carcinoma (Pca).
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negative predictive value was 75.7% (28/37 patients).
Analysis of the ROC curve of the initial PSA yielded an
area under the curve of 0.932 (Figure 4).
The Pca group showed no significant correlations between
the relative CD24 expression and various clinical parame-
ters, including age, clinical stage, initial PSA, pathological
stage, lymph node metastases, margins, grading (WHO),
and Gleason Score (Data not shown).
The follow-up (mean 3 years, range 2.4 – 3.3 years) dis-
closed biochemical progression in only two patients after
radical prostatectomy. The relative CD24 expression was
within the mean range of all Pca patients at 0.202 in the
first case (pat. 70) and 0.42 in the second one (pat. 74).
Two patients with palliative resections showed clinical
progression. Their relative CD24 expressions were 0.3552
(pat. 102) and 0.075 (pat. 105). These values did not cor-
respond to a significant correlation.
Discussion
The discovery of prostate-specific antigens (PSA) in 1970
[22] revolutionized the diagnostics of prostatic adenocar-
cinoma. The good sensitivity but poor specificity of this
serum marker has led, on the one hand, to a prognosti-
cally favorable stage shift towards increasingly smaller
tumors and, on the other hand, to numerous basically
superfluous prostate biopsies without tumor cells or with
extremely small foci. This offers a great challenge to the
assessing pathologists.
In recent years, a great number of new molecular markers
(DNA, RNA, protein) for many tumors, including prostate
cancer, have been discovered by microarray technologies
[23-28]. The clinical value of these upcoming new mark-
ers must now be determined in larger clinical studies.
One of these markers is CD24, which was recently
described by Kristiansen et al. based on RNA expression
profiling. 102 tissue samples from the prostate and 31
samples from lymph node metastases were examined. The
immunohistology used in their study achieved a sensitiv-
ity of only 48% in the prostate tissue samples and 68% in
the lymph node samples. This involved strong staining in
only 12% and 29% of the cases and only a very weak reac-
tion in most of them [9] there was no association with
tumor stage or grade [8,9]. However, since no benign con-
trol tissue was examined in this study, there was no calcu-
lated specificity. Kristiansen recently published the results
of an exemplary CD24 RT-PCR in several laser-microdis-
sected prostate tissue samples. Here a positive reaction
was likewise achieved in only 38.5% of the cases [8]. The
high heterogeneity of CD24 expression even within a
tumor of the same individual is apparently a problem not
only for the CD24 immunohistochemistry of the prostate
carcinoma but also for other tumor entities. The general
problem of reproducibility of an immunohistochemistry
is particularly accentuated by this [9].
Based on the RT-PCR protocol using LightCycler technol-
ogy, the present study revealed a highly significant eleva-
tion of tissue CD24 mRNA expression in Pca patients
compared to patients with a benign histology. The sensi-
tivity (correctly detected cancer patients) found in our
series (86.4%) is much better than that reported in other
series (38.5% and 48% [8,9]). The minimal tumor com-
ponent yielding a positive result is still unclear. If CD24
mRNA should be detectable not only in tissue but also in
prostatic secretions or even urine, the RT-PCR presented
here could serve as an important noninvasive supplement
to other procedures (digital rectal examination and serum
PSA) within the framework of cancer screening. We are
currently performing examinations in this connection.
However, the moderate specificity (correctly detected
patients without cancer) of the technique presented here
currently prevents this test from replacing or even supple-
menting other pathological procedures.
The histology of all patients was known in advance. All
BPH 55 patients had either a low preoperative PSA or a
previous biopsy to exclude malignancy. Thus we are deal-
ing with a PSA selection. This is corroborated by the far-
ROC-Curve of CD24 expression (blue); Area under the  curve 0,754 n = 114; Positiv (Prostate carcinoma, Pca) 59,  negative (benign prostatic hyperplasia, BPH) 55 patients With  a cutoff of 0.0498, the relative CD24-mRNA expression had  a sensitivity (detection of malignant samples) of 86.4% and a  specificity (detection of benign samples) of 47.3% Figure 3
ROC-Curve of CD24 expression (blue); Area under the 
curve 0,754 n = 114; Positiv (Prostate carcinoma, Pca) 59, 
negative (benign prostatic hyperplasia, BPH) 55 patients With 
a cutoff of 0.0498, the relative CD24-mRNA expression had 
a sensitivity (detection of malignant samples) of 86.4% and a 
specificity (detection of benign samples) of 47.3%.
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above-average AUC of the initial PSA (0.932) depicted in
Figure 4. Thus, a combination of the predictive values of
PSA and CD24-mRNA is not useful, at least not on the
basis of the present data.
Laser microdissection was primarily dispensed with, since
we wished to streamline the procedure, and Kristiansen et
al. have already described the heterogeneity of CD24
expression. We therefore analyzed tissue previously diag-
nosed for more than 50% tumor infiltration by an
uropathologist (J.K.).
The manufacturer designates PBGD as an ideal reference
and housekeeping gene and points out that this statement
is based on extensive internal series of experiments. The
PBGD expression level remained stable with widely vary-
ing experimental setups and was also within the RNA
expression range of the target gene. No other reference
genes were used.
Other study groups found the following results for other
tumor entities: Fogel shows that CD24 was expressed in
four of six breast cell lines (66.7% sensitivity) [11]. Droz
demonstrated that clear cell renal carcinomas always
show a strong reaction (100% sensitivity) [19]. The sensi-
tivity was 84% [29] for ovarian carcinomas and 76% [30]
for non-small-cell lung carcinomas. Huang showed that
CD24 mRNA is expressed in 66% of hepatocellular carci-
nomas (HCC) [12]. None of the above-mentioned studies
examined malignant compared to benign tissue. Thus
only conjectures can be made regarding the specificity of
the procedures.
We also found no correlation between CD24 expression
and clinical or pathological parameters like the tumor
stage or metastatic spread. Even specimens from patients
with early recurrences did not differ significantly from
those obtained in other stages of the disease. Only two of
13 Pca patients with a relative CD24 expression of over
0.3 are currently in disease progression (as indicated by a
PSA rise or clinical progression).
Our findings are entirely at variance with results previ-
ously described by Kristiansen et al., which led them to
assess CD24 as a strong independent predictor of recur-
rence not only for Pca but also for lung, breast, and ovar-
ian cancer [9,29-31]. Additional multicenter follow-up
studies are necessary to confirm the value of CD24 RT-
PCR as a prognostic marker.
Conclusion
Normalized CD24 transcript levels in 59 Pca cases were
increased 2.69-fold on the average when compared to 55
BPH cases. This difference was highly significant (p <
0.0001).
The procedure has a very good sensitivity (86.4%) and
moderate specificity (47.3%).
CD24 expression levels in Pca cases were not statistically
associated with the tumor or lymph node stage or with
grading (WHO), surgical margins, or the Gleason score.
The present study demonstrates the feasibility of quantita-
tive CD24 RNA transcript detection in prostatic tissues
even without previous laser microdissection. However,
the results do not yet signify a major improvement over
the usual standard tissue diagnostics.
If CD24 mRNA should be detectable not only in tissue but
also in prostatic secretions or even urine, the RT-PCR pre-
sented here could serve as an important noninvasive sup-
plement to other procedures (digital rectal examination
and serum PSA) within the framework of cancer screen-
ing.
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